Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous,
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …

Based on engineered or bacterial nucleases, the development of genome editing
technologies has opened up the possibility of directly targeting and modifying genomic …

Disease-associated single-nucleotide polymorphisms (SNPs) generally do not implicate
target genes, as most disease SNPs are regulatory. Many SNP-to-gene (S2G) linking …

Parkinson's disease is a complex neurodegenerative disorder for which both rare and
common genetic variants contribute to disease risk, onset, and progression. Mutations in …

Spatiotemporal gene expression programmes are orchestrated by transcriptional
enhancers, which are key regulatory DNA elements that engage in physical contacts with …

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by
degeneration of the substantia nigra pars compacta and by accumulation of α-synuclein in …

Alpha-synuclein (αS) is a conformationally plastic protein that reversibly binds to cellular
membranes. It aggregates and is genetically linked to Parkinson's disease (PD). Here, we …

Amyloids are a class of protein with unique self-aggregation properties, and their aberrant
accumulation can lead to cellular dysfunctions associated with neurodegenerative diseases …

During the past 12 years, genome-wide association studies (GWASs) have uncovered
thousands of genetic variants that influence risk for complex human traits and diseases. Yet …

The intestinal microbiota influence neurodevelopment, modulate behavior, and contribute to
neurological disorders. However, a functional link between gut bacteria and …